This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Beta-blockers , which slow the heart rate and reduce blood pressure. Anticoagulants to prevent bloodclots. BloodClots: An enlarged heart is more prone to developing bloodclots, which can lead to stroke or pulmonary embolism. Antiarrhythmics to help manage abnormal heart rhythms.
Stroke, Volume 55, Issue Suppl_1 , Page ATP214-ATP214, February 1, 2024. In-silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent-retriever design variations in a relatively time and cost-effective manner.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. In‐silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent‐retriever design variations in a relatively time and cost‐effective manner.
Patients had a valve annulus of 430 mm2 or less and anatomy suitable for either the Evolut PRO/PRO+/FX or the SAPIEN 3/3 Ultra. Researchers found no significant difference between groups in terms of a composite of death, disabling stroke or rehospitalization for heart failure—which occurred in 9.4% of those receiving the SAPIEN valve.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content